SMIN Therapeutics

SMIN Therapeutics is a biotechnology company developing oral medicines for autoimmune diseases. Its drug discovery platform studies interactions between proteins to identify therapeutic compounds, with an initial focus on the neonatal Fc receptor (FcRn), which regulates immunoglobulin G (IgG).

The company is developing small-molecule treatments intended to lower IgG implicated in autoimmune disease. Its approach aims to provide an orally administered alternative to injectable antibody therapies, with programmes at the research and preclinical development stages.